Literature DB >> 6530609

Dopamine metabolism in the central nervous system after discontinuation of L-dopa therapy in patients with Parkinson disease.

S Ogasahara, Y Nishikawa, M Takahashi, K Wada, Y Nakamura, S Yorifuji, S Tarui.   

Abstract

The dopamine turnover rate in the central nervous system (CNS) of parkinsonian patients was studied by means of the intravenous probenecid test during drug holiday (DH) and alternate day L-dopa therapy (ADDT). After L-dopa therapy was stopped, the dopamine turnover rate decreased more rapidly in patients with the marked wearing-off phenomenon than that in patients without fluctuation of symptoms. The lumbar CSF concentrations of L-dopa and 3-O-methyldopa of patients with and without wearing-off phenomenon were similar during L-dopa therapy. DH improved the effect of L-dopa on parkinsonian symptoms; it did not affect, however, the metabolism of exogenous L-dopa. The dopamine turnover rate in the CNS before L-dopa therapy or on on-days did not differ between patients tolerating and those not tolerating ADDT. However, it was significantly lower on off-days in patients not tolerating ADDT than in those tolerating ADDT. The relationship between dopamine storage in the CNS and the response to L-dopa therapy is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6530609     DOI: 10.1016/0022-510x(84)90003-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  The dopaminergic response in multiple system atrophy.

Authors:  A J Hughes; C Colosimo; B Kleedorfer; S E Daniel; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

Review 2.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

3.  Aberrant CpG Methylation Mediates Abnormal Transcription of MAO-A Induced by Acute and Chronic L-3,4-Dihydroxyphenylalanine Administration in SH-SY5Y Neuronal Cells.

Authors:  Zhaofei Yang; Xuan Wang; Jian Yang; Min Sun; Yong Wang; Xiaomin Wang
Journal:  Neurotox Res       Date:  2016-12-15       Impact factor: 3.911

4.  Deep brain stimulation in early Parkinson's disease: enrollment experience from a pilot trial.

Authors:  P D Charles; R M Dolhun; C E Gill; T L Davis; M J Bliton; M G Tramontana; R M Salomon; L Wang; P Hedera; F T Phibbs; J S Neimat; P E Konrad
Journal:  Parkinsonism Relat Disord       Date:  2011-11-21       Impact factor: 4.891

5.  Usefulness of movement time in the assessment of Parkinson's disease.

Authors:  M Zappia; R Montesanti; R Colao; A Quattrone
Journal:  J Neurol       Date:  1994-08       Impact factor: 4.849

6.  Inhibitory effect of thiacremonone on MPTP-induced dopaminergic neurodegeneration through inhibition of p38 activation.

Authors:  Chul Ju Hwang; Hee Pom Lee; Dong-Young Choi; Heon Sang Jeong; Tae Hoon Kim; Tae Hyung Lee; Young Min Kim; Dae Bong Moon; Sung Sik Park; Sun Young Kim; Ki-Wan Oh; Dae Yeon Hwang; Sang-Bae Han; Hwa-Jeong Lee; Jin Tae Hong
Journal:  Oncotarget       Date:  2016-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.